Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Carson O. Ray, Jr. who wrote (3686)	11/8/2000 8:14:28 PM
From: Gary Mohilner	Respond to of 5665

I believe todays reaction was partly caused by the announcement itself, and in part caused by the confirmation that the fact that in a Quiet Period they will release planned P.R. Now everyone knows that Friday the results of the Single Dose Trial to date will be released. Anyone who's read what Dr. Tolcher said about the drug in IBD has to be eagerly awaiting what will be said on Friday. In the announcement today, the big news was the fact that the trial of N901-DM1 will be conducted as a weekly Multi Dose Trial. This is great news as essentially the basic safety of the TAP drug is apparently being accepted so the single dose with redosing at three week intervals can be skipped. This is further validation of how well the trials of C242-DM1 have gone. Gary